AstraZeneca will acquire Fusion Pharmaceuticals for approximately $2.4 billion, including its next-generation radioconjugates such as FPI-2265, a potential treatment for metastatic castration-resistant prostate cancer. The company also announced recently positive results from a Phase 3 study assessing Imfinzi, or durvalumab, and Lynparza, or olaparib, as a treatment for endometrial cancer with mismatch repair proficient disease, where the median duration of response in this patient population was 18.7 months compared to 7.6 months in the control arm.